PATENT CLAIM ANALYSIS

Application Number: 16403038
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["424", "093210"]

Abstract:
The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Claim (Index 7):
The method of  claim 1 , wherein the MHC class I molecule is HLA-A*02.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 100.0
- Lexical Diversity: 1.87692
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16035300', '15677651', '16403058', '15461020', '15460654']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8527771842786308
- 35 USC 102 Novelty (BERT): 0.6348471011308446
- Combined Prediction Score: 0.8309841759638522
- Mean Citation Score: 702.412018
- Max Citation Score: 784.0143400000003
- Similarity Product: 523.3122964722802

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test